10x Genomics, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- 10x Genomics, Inc. (NASDAQ: TXG) develops and sells instruments, consumables, and software for analyzing biological systems at the single-cell and spatial level. The company offers Chromium instruments and single cell gene expression, immune profiling, ATAC-seq, and multiome analysis kits; Visium and Xenium platforms for spatial gene expression and protein analysis; and GEM-X technology for enhanced single-cell resolution; as well as bioinformatics software including Cell Ranger, Loupe Browser, and Space Ranger. Headquartered in Pleasanton, California, and founded in 2012, 10x Genomics operates globally, serving academic institutions, biotechnology firms, pharmaceutical companies, and clinical research organizations primarily in North America, Europe, and Asia. In recent developments, the company launched GEM-X in late 2023, significantly improving single-cell capture efficiency and data quality for genomic applications; expanded its Xenium in situ platform with Xenium Prime for high-throughput spatial biology workflows; and strengthened its capabilities through strategic collaborations with leading biotech firms on multi-omics research initiatives. These advancements position 10x Genomics at the forefront of the spatial genomics and single-cell sequencing segments within the life sciences tools industry.
Company News
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook
What 10x Genomics (TXG) Said on Its Q3 Earnings Call
Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics Reports Third Quarter 2026 Financial Results
Torex Gold Resources (TSE:TXG) Share Price Crosses Above 200-Day Moving Average – Here’s Why
10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
3 Promising Genomics Stocks to Add to Your Portfolio Now
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
Torex Gold Targets Growth, C$350M Returns and Morelos Expansion
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions